VR Logo

VistaGen Therapeutics Inc. (VTGN) download report


Healthcare | Biotechnology & Pharma Research

VistaGen Therapeutics Inc. (VTGN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).

IPO Date: 06-May-2016

CEO & Director: Mr. Shawn K. Singh J.D.

Founder, Pres & Chief Scientific Officer: Dr. H. Ralph Snodgrass Ph.D.

Listing: NASDAQ: VTGN

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.vistagen.com

Key Facts

Market cap: $183.93 Mln

Revenue (TTM): $1.51 Mln

Earnings (TTM): $-61.58 Mln

Cash: $83.70 Mln

Total Debt: $3.14 Mln

Insider's Holding: 0.33%

Liquidity: Low

52 Week range: $0.86 - 3.55

Shares outstanding: 206,528,000

10 Years Aggregate:

  • CFO: $-75.41 Mln
  • EBITDA: $-138.88 Mln
  • Net Profit: $-177.07 Mln

Stock Performance

Time Period VistaGen Therapeutics (VTGN) S&P BSE Sensex S&P Small-Cap 600
YTD-55.28-9.18-18.78
1 month-17.73-4.78-8.00
3 months-29.67-9.66-13.65
1 Year-72.310.81-17.19
3 Years6.3310.336.10
5 Years-14.1511.345.87
10 Years-24.0211.749.84
As on 01-Jul-2022
Year VistaGen Therapeutics (VTGN) S&P Small-Cap 600 S&P BSE Sensex
20210.5225.2721.99
2020181.289.5715.75
2019-54.0220.8614.38
201834.50-9.705.87
2017-70.1511.7327.91
2016-62.0924.741.95